Influenza Virus Infection
7
0
0
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
14%
1 trials in Phase 3/4
0%
0 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (7)
Volatile Organic Compounds Analysis by GC-MS for Diagnostic of Hospitalised Patients With Respiratory Infections Using Exhaled Breath
To Evaluate the Efficacy and Safety of TG-1000 Compared With Placebo in Adult Patients With Acute Uncomplicated Influenza Virus Infection
Study of Influenza Virus Infection in Children Hospitalized in Spain in Two Consecutive Influenza Seasons
Effect of Early Antiviral Therapy on Duration of Cough in Flu Patients
Effects of BCG on Influenza Induced Immune Response
Direct and Indirect Benefits of Influenza Vaccine Versus Placebo in Healthy Children
Direct and Indirect Benefits of Influenza Vaccination in Schools and Households